Kolon TissueGene (950160) Q2 2026 earnings summary

Executive summary

• Focus on cell and gene therapy platform (TG-C) for osteoarthritis, with U.S. Phase 3 clinical trials completed for knee OA and ongoing for other indications.

• Revenue primarily from B2B technology licensing and distribution of health/beauty products; no commercial sales of TG-C yet.

• Significant R&D investment, with pipeline expansion into hip OA, degenerative disc disease, and potential animal health applications.

• Multiple legal proceedings related to past product issues and shareholder claims.

Financial highlights

• 2026 H1 revenue: $1.51M (down from $3.63M in 2025 H1); operating loss: $(8.47)M (improved from $(15.70)M in 2025 H1).

• Net loss for 2026 H1: $(34.71)M; basic EPS: $(2.06).

• Cash and equivalents: $43.8M; convertible bonds outstanding: $37.3M.

• R&D expenses remain high, exceeding 2,100% of revenue.

Outlook and guidance

• U.S. Phase 3 TG-C 15302 topline data released post-period; primary endpoint not met, further analysis ongoing.

• TG-C 12301 study and follow-up analysis to inform future regulatory and commercialization strategy.

• Pipeline expansion into hip OA and DDD continues, with additional clinical trials planned.